Rationale for a New Low-Dose Triple Single Pill Combination for the Treatment of Hypertension
Authors:
- Anthony RodgersARAnthony Rodgers
- Abdul SalamASAbdul Salam
- William CushmanWCWilliam Cushman
- Asita de SilvaASAsita de Silva
- Gian Luca Di TannaGTGian Luca Di Tanna
- Sonali R. GnanenthiranSGSonali R. Gnanenthiran
- Diederick GrobbeeDiederick Grobbee
- Krzysztof NarkiewiczKNKrzysztof Narkiewicz
- Dike OjjiDODike Ojji
- Suzanne OparilSOSuzanne Oparil
- Neil PoulterNPNeil Poulter
- Markus P. SchlaichMSMarkus P. Schlaich
Open Access
- 14 February 2024
- journal article
- research article
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 18
Abstract
Two recent large trials showed the potential of single pill combinations (SPCs) with ≥3 low-dose components among people with hypertension who were untreated or receiving monotherapy. In both trials, these ‘hypertension polypills’ were superior to usual care, achieving >80% BP control without increasing withdrawal due to side effects. However, there are no such products available for prescribers. To address this unmet need, George Medicines developed GMRx2 with telmisartan/amlodipine/indapamide in three strengths (mg): 10/1.25/0.625, 20/2.5/1.25; 40/5/2.5. Two pivotal trials are ongoing to support FDA submission for the treatment of hypertension, including initial treatment. These assess efficacy and safety of GMRx2 compared to: placebo, and each of the three possible dual combinations. Regulatory submissions are planned for 2024, with the aim of providing access to GMRx2 in developed and developing regions. Wider implementation of GMRx2-based treatment strategies will be guided by further research to inform access and appropriate scale up.Keywords
This publication has 47 references indexed in Scilit:
- Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri LankaJAMA, 2018
- Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and MortalityJAMA Cardiology, 2017
- Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic reviewThe Lancet, 2017
- ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure — A network meta-analysisInternational Journal of Cardiology, 2016
- Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized TrialsMayo Clinic Proceedings, 2016
- Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study dataThe Lancet, 2016
- Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income CountriesJAMA, 2013
- Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY studyJournal of the American Society of Hypertension, 2012
- Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 TrialsThe American Journal of Medicine, 2009
- Incidence and Characteristics of Angioedema Associated With EnalaprilArchives of internal medicine (1960), 2005